Literature DB >> 11763413

Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS.

T Forsström1, J Tuominen, J Karkkäinen.   

Abstract

A new method for the determination of N,N-dimethyl-5-hydroxytryptamine (bufotenine), N,N-dimethyltryptamine (DMT)*, 5-methoxy-N,N-dimethyltryptamine (5-MeODMT), and N-methyltryptamine (NMT) was developed using high-performance liquid chromatography-mass spectrometry (HPLC-MS). Identification of the analytes is based on liquid chromatographic retention times of analytes and two fragment ions produced by a triple quadrupole mass spectrometer. Quantification is based on electrospray ionization (ESI), and multiple reaction monitoring (MRM) was also utilized for getting better selectivity. The analytes and internal standard were separated from the urine matrix by solid-phase extraction (SPE). The method was applied for the determination of these compounds in urine samples of patients from surgical, medical and psychiatric wards. Of the dimethylated amines, only bufotenine was found in significant amounts (up to 34 microg/L). In keeping with our earlier results, the bufotenine excretion of psychiatric patients was found to be higher than that of the somatic patients. Method, procedure, considerations, statistical evaluations and urine sample spectra are presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11763413     DOI: 10.1080/003655101753218319

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  7 in total

1.  Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.

Authors:  Elena L Paley; Galina Denisova; Olga Sokolova; Natalia Posternak; Xukui Wang; Anna-Liisa Brownell
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS.

Authors:  Rafaela Martin; Jennifer Schürenkamp; Angela Gasse; Heidi Pfeiffer; Helga Köhler
Journal:  Int J Legal Med       Date:  2012-11-27       Impact factor: 2.686

3.  Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Bioanalysis       Date:  2009-04       Impact factor: 2.681

4.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

Review 5.  Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Jerrold C Winter; Ai-Ming Yu
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

Review 6.  A narrative synthesis of research with 5-MeO-DMT.

Authors:  Anna O Ermakova; Fiona Dunbar; James Rucker; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2021-10-19       Impact factor: 4.153

Review 7.  The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).

Authors:  Johannes T Reckweg; Malin V Uthaug; Attila Szabo; Alan K Davis; Rafael Lancelotta; Natasha L Mason; Johannes G Ramaekers
Journal:  J Neurochem       Date:  2022-03-08       Impact factor: 5.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.